Alnylam Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,714	2,248	1,828	1,037	844.29
Revenue Growth (YoY)	65.19%	22.97%	76.23%	22.88%	71.31%
Cost of Revenue	681.87	323.37	310.41	168.82	140.14
Gross Profit	3,032	1,925	1,518	868.6	704.14
Selling, General & Admin	1,211	975.53	795.65	770.66	620.64
Research & Development	1,320	1,126	1,004	883.02	792.16
Operating Expenses	2,530	2,102	1,800	1,654	1,413
Operating Income	501.58	-176.89	-282.18	-785.07	-708.65
Interest Expense	-252.63	-141.86	-121.22	-155.97	-143.02
Interest & Investment Income	111.47	121.99	95.56	24.81	1.58
Other Non Operating Income (Expenses)	-34.96	-177.6	-108.74	-100.86	-57.75
EBT Excluding Unusual Items	325.46	-374.35	-416.57	-1,017	-907.84
Gain (Loss) on Sale of Investments	-2.31	-3.02	-16.94	-33.31	55.7
Other Unusual Items	-	-	-	-76.59	-
Pretax Income	323.15	-377.38	-433.52	-1,127	-852.14
Income Tax Expense	9.41	-99.22	6.73	4.16	0.68
Net Income	313.75	-278.16	-440.24	-1,131	-852.82
Net Income to Common	313.75	-278.16	-440.24	-1,131	-852.82
Shares Outstanding (Basic)	131	128	125	122	118
Shares Outstanding (Diluted)	135	128	125	122	118
Shares Change (YoY)	5.51%	2.20%	2.64%	2.73%	3.01%
EPS (Basic)	2.39	-2.18	-3.52	-9.30	-7.20
EPS (Diluted)	2.33	-2.18	-3.52	-9.30	-7.20
Free Cash Flow	465.38	-42.59	41.95	-613.33	-718.07
Free Cash Flow Per Share	3.46	-0.33	0.34	-5.04	-6.06
Gross Margin	81.64%	85.62%	83.02%	83.73%	83.40%
Operating Margin	13.51%	-7.87%	-15.43%	-75.68%	-83.94%
Profit Margin	8.45%	-12.37%	-24.08%	-109.04%	-101.01%
Free Cash Flow Margin	12.53%	-1.89%	2.29%	-59.12%	-85.05%
EBITDA	557.24	-120.22	-228.12	-740.6	-661.09
EBITDA Margin	15.00%	-5.35%	-12.48%	-71.39%	-78.30%
D&A For EBITDA	55.66	56.67	54.05	44.47	47.57
EBIT	501.58	-176.89	-282.18	-785.07	-708.65
EBIT Margin	13.51%	-7.87%	-15.43%	-75.67%	-83.94%
Effective Tax Rate	2.91%	-	-	-	-
Revenue as Reported	3,714	2,248	1,828	1,037	844.29
Advertising Expenses	36	29.7	12.4	11.7	-

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q